American pharmaceutical giants are among the first to launch mass production of the coronavirus vaccine. Yet, they cannot determine the final cost of the product as the difference in price turns out to be very significant.
For example, US biotechnology company Moderna has set the price for a course of a vaccine against coronavirus infection at $50–60. Besides, this price appeared in commercial offers and in negotiations with potential buyers. Nevertheless, other pharma companies offered far modest price. Pfizer and Biontech have estimated its vaccine at $19.5 per dose, while AstraZeneca requires only three to four dollars, which is the cheapest offer. Taking into account these price tags, there is no need to be a financial genius to understand how difficult it will be for Moderna to compete with other manufacturers. Besides, Moderna voiced a preliminary cost of the product. It means that the final price may be much higher. This puts the company in an unfavorable position as the buyers are unlikely to be attracted by such an offer.
For now, companies are mulling over the price only for the US market. US President Donald Trump has already mentioned the possibility of exporting a vaccine to other countries. Notably, export prices can be set based on the level of income of the population in a particular country.
*The market analysis posted here is meant to increase your awareness, but not to give instructions to make a trade.
-
Grand Choice
Contest by
InstaForexInstaForex always strives to help you
fulfill your biggest dreams.JOIN CONTEST -
Chancy DepositDeposit your account with $3,000 and get $8000 more!
In March we raffle $8000 within the Chancy Deposit campaign!
Get a chance to win by depositing $3,000 to a trading account. Having fulfilled this condition, you become a campaign participant.JOIN CONTEST -
Trade Wise, Win DeviceTop up your account with at least $500, sign up for the contest, and get a chance to win mobile devices.JOIN CONTEST